Study	Reason for exclusion
Abe 2017	Post hoc subgroup analyses of an already included trial
Abufarag 2010	Other treatment
Adsit 2017	Post hoc subgroup analyses of an already included trial
Akhyani 2010	Other treatment
Altmeyer 1994	Not plaque‐type psoriasis
Angsten 2007	Not a trial
Anonymous 2005	Not a trial
Anonymous 2008	Not a trial
Anonymous 2019	Not a randomised trial
Araujo 2017	Not moderate‐to‐severe psoriasis
Araujo 2019	Not moderate‐to‐severe psoriasis
Arifov 1998	Not a randomised trial
Armati 1972	Other treatment
Augustin 2017	Dose de‐escalation strategy study
Avgerinou 2011	Not a randomised trial
Bachelez 2017	Post hoc subgroup analyses of an already included trial
Bagel 2017a	Open‐label extension restricted to good responders
Bagel 2017b	Not a randomised trial
Bagel 2017c	Not moderate‐to‐severe psoriasis
Bagel 2018b	Not a randomised trial
Bagherani 2017	Commentary/editorial
Bagot 1994	Other treatment
Bartlett 2008	Not a trial
Barzegari 2004	Other treatment
Batchelor 2009	Not a trial
Bayerl 1992	Other treatment
Beissert 2009	Other treatment
Berbis 1989	Assessment < 8 weeks
Bhat 2017	Post hoc subgroup analyses of an already included trial
Bhuiyan 2010	Other treatment
Bian 2018	Open‐label extension restricted to good responders
Bigby 2004	Not a trial
Bissonnette 2006	Other treatment
Bissonnette 2010	Other treatment
Bissonnette 2017a	Open‐label extension restricted to good responders
Bissonnette 2017b	Not moderate‐to‐severe psoriasis
Bissonnette 2018	Not moderate‐to‐severe psoriasis
Bjerke 1989	Other treatment
Blauvelt 2016a	Ineligible study design
Blauvelt 2016b	Open‐label extension restricted to good responders
Blauvelt 2017a	Pooled trials
Blauvelt 2017b	Open‐label extension restricted to good responders
Blauvelt 2017c	Open‐label extension restricted to good responders
Blauvelt 2017d	Open‐label extension restricted to good responders
Blauvelt 2017e	Pooled trials
Blauvelt 2017f	Ineligible study design
Blauvelt 2017g	Open‐label extension restricted to good responders
Blauvelt 2017h	Open‐label extension restricted to good responders
Blauvelt 2017i	Open‐label extension restricted to good responders
Blauvelt 2017j	Pooled trials
Blauvelt 2017k	Open‐label extension restricted to good responders
Blauvelt 2018a	Not a randomised trial
Blauvelt 2018b	Open‐label extension restricted to good responders
Blauvelt 2018c	Open‐label extension restricted to good responders
Blauvelt 2018d	Pooled trials
Blauvelt 2018e	Pooled trials
Blauvelt 2018f	Pooled trials
Blauvelt 2018g	Pooled trials
Blauvelt 2018h	Pooled trials
Blauvelt 2018i	Pooled trials
Branigan 2017	Open‐label extension restricted to good responders
Brasil 2012	Ineligible study design
Brasil 2013	Ineligible patient population
Brasil 2016	Ineligible patient population
Burden 2017	Commentary/editorial
Burkhardt 2017	Ineligible study design
Callis Duffin 2017	Comparison of the same drug with the same dosages
Cassano 2006	Identical dosing regimens
Cassano 2010	Not a trial
Cather 2006	Dose‐ranging after remission
Cather 2018	Ineligible patient population
Chakravadhanula 2017	Ineligible intervention
Chapman 2018	Ineligible study design
ChiCTR‐INR‐16009710	Assessment at 4 weeks
Chládek 2002	Basic science (aim of study: to understand the physiopathology of the disease)
Chodorowska 1999a	Not a trial
Chodorowska 1999b	Not a trial
Choi 2017	Not moderate‐to‐severe psoriasis
Crowley 2018a	Not moderate‐to‐severe psoriasis
Crowley 2018b	Open‐label extension restricted to good responders
CTRI/2018/01/011373	2 different schemas of administration (same drug, same dosage)
De Jong 2003	Other treatment
De Mendizabal 2017	Post hoc subgroup analyses of an already included trial
Dubiel 1972	Not a trial
Duffin 2016	Comparison of 2 different ways of drug injection for the same drug and the same dosage
Duffin 2017	Ineligible study design
Ecker‐Schlipf 2009	Other treatment
Edson‐Heredia 2013	Post hoc subgroup analyses of an already included trial
Egeberg 2016	Commentary/editorial
Elewski 2007	Pooled trials
Elewski 2017	Post hoc subgroup analyses of an already included trial
Elewski 2018a	Ineligible study design
Elewski 2018b	Ineligible study design
Ellis 1986	Assessment < 8 weeks
Ellis 2001	Another intervention
Ellis 2002	Medico‐economic study
Ellis 2012	Other treatment
Engst 1989	Assessment < 8 weeks
Erkko 1997	Basic science (aim of study: to understand the physiopathology of the disease)
EUCTR2007‐004328‐18‐FR	Ineligible intervention
EUCTR2012‐005685‐35‐DE	Withdrawn trial, NCT01815723
EUCTR2016‐001593‐15‐ES	Withdrawal trial, DEEP Study
EUCTR2016‐003592‐21‐GB	Withdrawal trial
EUCTR2018‐001021‐10‐SE	Not moderate‐to‐severe psoriasis
EUCTR2019‐000817‐35‐DE	Not moderate‐to‐severe psoriasis
Ezquerra 2007	Other treatment
Feldman 2017	Not moderate‐to‐severe psoriasis
Fernandes 2013	Not a trial
Fernandez 2017	Not a randomised trial
Finzi 1993	Other treatment
Fitz 2018	Post hoc subgroup analyses of an already included trial
Fleischer 2005	Other treatment
Foley 2017	Pooled trials
Foley 2018	Pooled trials
Fredriksson 1971	Other treatment
Fredriksson 1978	Other treatment
Friedrich 2001	Other treatment
Gambichler 2011	Other treatment
Ganguly 2004	Pooled trials
Gil 2003	Not a randomised trial
Glatt 2017	Ineligible study design
Goerz 1978	Not a trial
Gold 2018	Ineligible study design
Goll 2017	Not moderate‐to‐severe psoriasis
Goll 2018	Ineligible study design
Gollnick 1988	Other treatment
Gollnick 1993	Other treatment
Gollnick 2002	Other treatment
Gordon 2014	Ineligible study design
Gordon 2015	Ineligible study design
Gordon 2018a	Open‐label extension restricted to good responders
Gordon 2018b	Post hoc subgroup analyses of an already included trial
Gordon 2018c	Pooled trials
Gordon 2018d	Post hoc subgroup analyses of an already included trial
Gottlieb 2002	Other treatment
Gottlieb 2003b	Other treatment
Gottlieb 2003c	Open‐label extension restricted to good responders
Gottlieb 2004b	Pooled trials
Gottlieb 2005	Other treatment
Gottlieb 2006a	Ineligible intervention
Gottlieb 2006b	Ineligible intervention
Gottlieb 2010	Cross‐over trial
Gottlieb 2016	Pooled trials
Gottlieb 2017a	Not moderate‐to‐severe psoriasis
Gottlieb 2017b	Not moderate‐to‐severe psoriasis
Gottlieb 2017c	Post hoc subgroup analyses of an already included trial
Gottlieb 2017d	Pooled trials
Gottlieb 2018a	Pooled trials
Gottlieb 2018b	Pooled trials
Goupille 1995	Not a randomised trial
Goupille 2018	Not moderate‐to‐severe psoriasis
Griffiths 1998	Other treatment
Griffiths 2002a	Pooled trials
Griffiths 2002b	Pooled trials
Griffiths 2005	Pooled trials
Griffiths 2010	Open‐label extension restricted to good responders
Griffiths 2016	Post hoc subgroup analyses of an already included trial
Griffiths 2017	Open‐label extension restricted to good responders
Griffiths 2018a	Ineligible study design
Griffiths 2018b	Post hoc subgroup analyses of an already included trial
Griffiths 2018c	Pooled trials
Grim 2000	Basic science (aim of study: to understand the physiopathology of the disease)
Grossman 1994	Other treatment
Guenther 2020	Not moderate‐to‐severe psoriasis
Gulliver 1996	Not a trial
Gupta 2005	Other treatment
Gupta 2007	Other treatment
Gupta 2008	Other treatment
Han 2013	Other treatment
Hashizume 2007	Comparison of 2 methods of administration
Hawkes 2018	Ineligible study design
Heule 1988	Assessment < 8 weeks
Ho 2010	Other treatment
Holzer 2020	No efficacy or safety assessment ‐ the study assessed cardiovascular outcomes
Hsu 2018	Post hoc subgroup analyses of an already included trial
Hunter 1972	Other treatment
Iest 1989	Not a randomised trial
Imafuku 2017	Post hoc subgroup analyses of an already included trial
Iversen 2018	Ineligible comparator
Jackson 2018	Ineligible study design
Jacobe 2008	Another intervention
JapicCTI‐194706 2019	Comparison of different schemas of administraton (same drug, same dosage)
jRCTs041180012 2018	Not moderate‐to‐severe psoriasis
Kaur 2018	Ineligible outcomes
Kavanaugh 2009	Not a randomised trial
Kemeny 2019	Post hoc subgroup analyses of an already included trial
Kimball 2008	Drug withdrawn for safety reasons
Kimball 2011	Drug withdrawn for safety reasons
Kimball 2018	Ineligible study design
Koo 1998	Other treatment
Kopp 2015	Phase 1 trial
Kragballe 1989	Other treatment
Krishnan 2005	Pooled trials
Krishnan 2018	Pooled trials
Kristensen 2017	Not moderate‐to‐severe psoriasis
Krueger 1980	Other treatment
Krueger 2002a	Another intervention
Krueger 2002b	Not a trial
Krueger 2003	Not a trial
Krueger 2012	Phase 1 trial
Krueger 2015	Phase 1 trial
Krueger 2016b	Phase I trial
Krupashankar 2014	Another intervention
Kuijpers 1998	Other treatment
Lajevardi 2015	Other treatment
Lambert 2018	Post hoc subgroup analyses of an already included trial
Langewouters 2005	Other treatment
Langley 2006	Other treatment
Langley 2010	Other treatment
Langley 2016	Open‐label extension restricted to good responders
Langley 2018	Ineligible study design
Langner 2004	Not plaque‐type psoriasis
Lauharanta 1989	Other treatment
Lawrence 1983	Other treatment
Leavell 1970	Other treatment
Lebwohl 2003	Another intervention
Lebwohl 2003a	Pooled trials
Lebwohl 2009	Pooled trials
Lebwohl 2012	Other treatment
Lebwohl 2013	Other treatment
Ledo 1988	Other treatment
Legat 2005	Other treatment
Leonardi 2010a	Pooled trials
Leonardi 2010b	Not a randomised trial
Leonardi 2010c	Pooled trials
Leonardi 2011a	Open‐label extension restricted to good responders
Leonardi 2011b	Not plaque‐type psoriasis
Levell 1995	Other treatment
Li 2018	Post hoc subgroup analyses of an already included trial
Liang 1995	Assessment < 8 weeks
Louw 2017	Open‐label extension restricted to good responders
Lui 2011	Other treatment
Lui 2012	Other treatment
Lynde 2012	Other treatment
Macdonald 1972	Not a randomised trial
Mahrle 1995	Other treatment
Malik 2010	Other treatment
Marecki 2004	Other treatment
Marks 1986	Not a randomised trial
Mate 2017	Not moderate‐to‐severe psoriasis
Mate 2018	Open‐label extension restricted to good responders
McInnes 2013	Pooled trials
McInnes 2017	Not moderate‐to‐severe psoriasis
Mease 2011	Drug withdrawn for safety reasons
Mease 2016a	Not moderate‐to‐severe psoriasis
Mease 2016b	Not moderate‐to‐severe psoriasis
Mease 2017a	Not moderate‐to‐severe psoriasis
Mease 2017b	Not moderate‐to‐severe psoriasis
Mease 2017c	Not moderate‐to‐severe psoriasis
Mease 2018	Not moderate‐to‐severe psoriasis
Meffert 1989	Other treatment
Menon 2012	Basic science (aim of study: to understand the physiopathology of the disease)
Menter 2007	Pooled trials
Menter 2014	Drug withdrawn for safety reasons
Merola 2017	Post hoc subgroup analyses of an already included trial
Merola 2018	Not moderate‐to‐severe psoriasis
Meyer 2011	Other treatment
Mittal 2009	Other treatment
Moller 2009	Other treatment
Monk 1986	Not a randomised trial
Montgomery 1993	Other treatment
Mrowietz 1991	The 2 study arms compared the same molecule with the same dosage
Mrowietz 2012	Pooled trials
Narang 2012	Other treatment
Nash 2015	Not moderate‐to‐severe psoriasis
NCT00106847	Dose de‐escalation strategy study
NCT00111111	Dose de‐escalation strategy study
NCT00258713	Ineligible intervention
NCT00358670	Open‐label extension restricted to good responders
NCT00377325	Withdrawal trial
NCT00438360	Open‐label extension restricted to good responders
NCT00585650	Ineligible patient population
NCT00645892	Open‐label extension restricted to good responders
NCT00646191	Open‐label extension restricted to good responders
NCT00647400	Open‐label extension restricted to good responders
NCT00832364	Withdrawal trial
NCT01163253	Not a randomised trial
NCT01235442	Ineligible intervention
NCT01276847	Phase I trial
NCT01412944	Open‐label extension restricted to good responders
NCT01443338	Ineligible comparator
NCT01544595	Open‐label extension restricted to good responders
NCT01550744	Open‐label extension restricted to good responders
NCT01624233	Not a randomised trial
NCT01722214	Not moderate‐to‐severe psoriasis
NCT01806597	Ineligible patient population
NCT01815723	Withdrawal trial
NCT01828086	Phase I trial
NCT01936688	Withdrawal trial
NCT02362789	Withdrawal trial
NCT02409667	Open‐label extension restricted to good responders
NCT02798211	Not moderate‐to‐severe psoriasis
NCT03010527	Open‐label extension restricted to good responders
NCT03020199	Ineligible comparator
NCT03073213	Phase I trial
Nemoto 2018	Phase I trial
Nieboer 1990	Other treatment
Nijsten 2008	Not a trial
Noda 2011	Not a randomised trial
Noor 2017	Not a randomised trial
Novotny 1973	Not a trial
Nyfors 1978	Not a trial
Okubo 2019	Open‐label extension restricted to good responders
Orfanos 1978	Other treatment
Orfanos 1979	Other treatment
Ortonne 2008	Comparison of 2 schemes of administration
Ortonne 2011	Other treatment
Osamu 2014	Phase 1 trial
Page 2020	Phase 1 trial
Pakozdi 2018	Post hoc subgroup analyses of an already included trial
Papp 2001	Other treatment
Papp 2006	Other treatment
Papp 2008	Other treatment
Papp 2009	Pooled data
Papp 2011a	Pooled trials
Papp 2011b	Drug withdrawn for safety reasons
Papp 2011c	Drug withdrawn for safety reasons
Papp 2012d	Phase 1 trial
Papp 2012e	Pooled trials
Papp 2017c	Open‐label extension restricted to good responders
Papp 2018a	Ineligible outcomes
Papp 2018b	Ineligible outcomes
Park 2013	Other treatment
Paul 2012	Other treatment
Paul 2014	Other treatment
Paul 2018	Pooled trials
Perks 2017	Ineligible study design
Pettit 1979	Assessment < 8 weeks
Petzelbauer 1990	Not a randomised trial
Piascik 2003	Not a trial
Ports 2013	Other treatment
Puig 2018	Ineligible outcomes
Punwani 2012	Other treatment
Rabasseda 2012	Not a trial
Radmanesh 2011	Comparison of 2 schemes of administration
Raman 1998	Other treatment
Reich 2004	Ineligible intervention
Reich 2011	Pooled trials
Reich 2014	Other treatment
Reich 2016a	Ineligible study design
Reich 2016b	Ineligible study design
Reich 2017a	Ineligible study design
Reich 2017b	Open‐label extension restricted to good responders
Reich 2017c	Pooled trials
Reich 2018a	Ineligible outcomes
Reich 2018b	Ineligible
Reich 2018c	Open‐label extension restricted to good responders
Reitamo 1999	Other treatment
Reitamo 2001	Other treatment
Rim 2003	Other treatment
Rinsho Iyaku 1991	Other treatment
Ritchlin 2006a	Not a randomised trial
Ritchlin 2006b	Not a randomised trial
Romiti 2017	Post hoc subgroup analyses of an already included trial
RPCEC00000201	Ineligible intervention
Ryan 2018	Not moderate‐to‐severe psoriasis
Saeki 2017	Not a randomised trial
Salim 2006	Other treatment
Scholl 1981	Other treatment
Schopf 1998	Other treatment
Schulze 1991	Other treatment
Shintani 2011	Comparison of 2 schemes of administration
Shiohara 1992	Not a trial
Shupack 1997	Not a trial
Simonova 2005	Other treatment
Sinclair 2017	Pooled trials
Sofen 2011	Basic science (aim of study: to understand the physiopathology of the disease)
Sofen 2014	Phase 1 trial
Spadaro 2008	Not a trial
Spuls 2012	Not a trial
Stein Gold 2018	Not moderate‐to‐severe psoriasis
Sticherling 1994	Not a trial
Strober 2004	Not a trial
Strober 2012	Not a randomised trial
Strober 2017a	Pooled trials
Strober 2017b	Not moderate‐to‐severe psoriasis
Strober 2017c	Ineligible outcomes
Strober 2018	Ineligible study design
Sun 2019	Not psoriasis
Sweetser 2006	Cross‐over trial
Syversen 2020	NCT03074656 ‐ pragmatic trial according to anti TNF dosages
Talwar 1992	Not a randomised trial
TCTR20190705002	Comparison of 2 different schema of administration (same drug same dosage)
Tejasvi 2012	Other treatment
Thaçi 2002	The 2 study arms compared the same molecule with the same dosage
Thaçi 2010	Other treatment
Thaçi 2018	Ineligible outcomes
Tong 2008	Other treatment
Tsakok 2018	Commentary/editorial
Vaclavkova 2014	Another intervention
Valenzuela 2017	Post hoc subgroup analyses of an already included trial
Van de Kerkhof 2017	Post hoc subgroup analyses of an already included trial
Van Joost 1988	Assessment < 8 weeks
Vena 2005	Comparison of 2 schemes of administration
Vena 2012	Other treatment
Viglioglia 1978	Not a trial
Witkamp 1995	Other treatment
Wolf 2012	Other treatment
Wright 1966	Not a randomised trial
Wu 2015	Other treatment
Yan 2011	Another intervention
Yesudian 2013	Other treatment
Yoon 2007	Dose‐escalation study
Yosipovitch 2018	Not moderate‐to‐severe psoriasis
Zachariae 2008	Other treatment
Zhang 2007	Other treatment
Zhang 2009a	Other treatment
Zhang 2009b	Other treatment
Zhu 2009	Pooled trials
Zhuang 2016	Phase 1 trial
Zobel 1987	Not a trial